{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:46:01Z","timestamp":1786981561856,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s11154-024-09893-x","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T23:24:05Z","timestamp":1720826645000},"page":"817-825","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Inhibitors of apolipoprotein C3, triglyceride levels, and risk of pancreatitis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5620-6468","authenticated-orcid":false,"given":"Walter","family":"Masson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan P.","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Barbagelata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Siniawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,13]]},"reference":[{"issue":"4","key":"9893_CR1","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/MOL.0000000000000425","volume":"28","author":"DJ Galton","year":"2017","unstructured":"Galton DJ. Clarifying complex inheritance: apolipoprotein C3 and atherosclerosis. Curr Opin Lipidol. 2017;28(4):308\u201312. https:\/\/doi.org\/10.1097\/MOL.0000000000000425.","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"9893_CR2","doi-asserted-by":"publisher","first-page":"100475","DOI":"10.1016\/j.jlr.2023.100475","volume":"65","author":"KE Bornfeldt","year":"2024","unstructured":"Bornfeldt KE. Apolipoprotein C3: form begets function. J Lipid Res. 2024;65(1):100475. https:\/\/doi.org\/10.1016\/j.jlr.2023.100475.","journal-title":"J Lipid Res"},{"key":"9893_CR3","doi-asserted-by":"publisher","first-page":"117501","DOI":"10.1016\/j.atherosclerosis.2024.117501","volume":"391","author":"E Gagnon","year":"2024","unstructured":"Gagnon E, Arsenault BJ. Drug target mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases prevention. Atherosclerosis. 2024;391:117501. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117501.","journal-title":"Atherosclerosis"},{"issue":"1","key":"9893_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12933-022-01525-5","volume":"21","author":"RS Patel","year":"2022","unstructured":"Patel RS, Pasea L, Soran H, Downie P, Jones R, Hingorani AD, et al. Elevated plasma triglyceride concentration and risk of adverse clinical outcomes in 1.5 million people: a CALIBER linked electronic health record study. Cardiovasc Diabetol. 2022;21(1):102. https:\/\/doi.org\/10.1186\/s12933-022-01525-5.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"9893_CR5","doi-asserted-by":"publisher","first-page":"14096","DOI":"10.1038\/s41598-018-32337-x","volume":"8","author":"L Kiss","year":"2018","unstructured":"Kiss L, F\u0171r G, M\u00e1trai P, Hegyi P, Iv\u00e1ny E, Cazacu IM, et al. The effect of serum triglyceride concentration on the outcome of acute pancreatitis: systematic review and meta-analysis. Sci Rep. 2018;8(1):14096. https:\/\/doi.org\/10.1038\/s41598-018-32337-x.","journal-title":"Sci Rep"},{"issue":"2","key":"9893_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.tcm.2019.03.001","volume":"30","author":"V Chyzhyk","year":"2020","unstructured":"Chyzhyk V, Brown AS. Familial chylomicronemia syndrome: a rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis. Trends Cardiovasc Med. 2020;30(2):80\u20135. https:\/\/doi.org\/10.1016\/j.tcm.2019.03.001.","journal-title":"Trends Cardiovasc Med"},{"issue":"9","key":"9893_CR7","doi-asserted-by":"publisher","first-page":"626","DOI":"10.7326\/M19-0203","volume":"170","author":"A Chait","year":"2019","unstructured":"Chait A, Eckel RH. The chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment. Ann Intern Med. 2019;170(9):626\u201334. https:\/\/doi.org\/10.7326\/M19-0203.","journal-title":"Ann Intern Med"},{"key":"9893_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.12997\/jla.2024.13.1.2","volume":"13","author":"B Tomlinson","year":"2024","unstructured":"Tomlinson B, Wu QY, Zhong YM, Li YH. Advances in Dyslipidaemia treatments: focusing on ApoC3 and ANGPTL3 inhibitors. J Lipid Atheroscler. 2024;13:2\u201320. https:\/\/doi.org\/10.12997\/jla.2024.13.1.2.","journal-title":"J Lipid Atheroscler"},{"key":"9893_CR9","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1400283","volume":"373","author":"D Gaudet","year":"2015","unstructured":"Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373:438\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1400283.","journal-title":"N Engl J Med"},{"key":"9893_CR10","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.2337\/dc16-0126","volume":"39","author":"A Digenio","year":"2016","unstructured":"Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, et al. Antisense-mediated lowering of plasma apolipoprotein C-III by Volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. Diabetes Care. 2016;39:1408\u201315. https:\/\/doi.org\/10.2337\/dc16-0126.","journal-title":"Diabetes Care"},{"key":"9893_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381:531\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1715944.","journal-title":"N Engl J Med"},{"key":"9893_CR12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","volume":"9","author":"I Gouni-Berthold","year":"2021","unstructured":"Gouni-Berthold I, Alexander VJ, Yang Q, Hurh E, Steinhagen-Thiessen E, Moriarty PM, et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9:264\u201375. https:\/\/doi.org\/10.1016\/S2213-8587(21)00046-2.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"9893_CR13","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacl.2022.08.008","volume":"16","author":"EA Oral","year":"2022","unstructured":"Oral EA, Garg A, Tami J, Huang EA, O\u2019Dea LStL, Schmidt H, et al. Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: results of the BROADEN study: Volanesorsen in FPLD; the BROADEN Study. J Clin Lipidol. 2022;16:833\u201349. https:\/\/doi.org\/10.1016\/j.jacl.2022.08.008.","journal-title":"J Clin Lipidol"},{"key":"9893_CR14","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","volume":"43","author":"JC Tardif","year":"2022","unstructured":"Tardif JC, Karwatowska-Prokopczuk E, St Amour E, Ballantyne CM, Shapiro MD, Moriarty PM, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022;43:1401\u201312. https:\/\/doi.org\/10.1093\/eurheartj\/ehab820.","journal-title":"Eur Heart J"},{"key":"9893_CR15","doi-asserted-by":"publisher","unstructured":"Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, et al. Olezarsen for Hypertriglyceridemia in patients at High Cardiovascular Risk. N Engl J Med. 2024 Apr;7. https:\/\/doi.org\/10.1056\/NEJMoa2402309.","DOI":"10.1056\/NEJMoa2402309"},{"key":"9893_CR16","doi-asserted-by":"publisher","unstructured":"Gaudet D, Pall D, Watts GF, Nicholls SJ, Rosenson RS, Modesto K et al. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 Randomized Clinical Trial. JAMA Cardiol 2024 Apr 7:e240959. https:\/\/doi.org\/10.1001\/jamacardio.2024.0959.","DOI":"10.1001\/jamacardio.2024.0959"},{"key":"9893_CR17","doi-asserted-by":"publisher","unstructured":"Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, Arca M, Ballantyne CM, et al. Olezarsen, Acute Pancreatitis, and familial chylomicronemia syndrome. N Engl J Med. 2024 Apr;7. https:\/\/doi.org\/10.1056\/NEJMoa2400201.","DOI":"10.1056\/NEJMoa2400201"},{"key":"9893_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s12020-022-03025-8","volume":"76","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Li T, Tan P, Du Y, Huang Z, Shi H, et al. Efficacy and safety of the apolipoprotein C-III inhibitor Volanesorsen: a systematic evaluation and meta-analysis. Endocrine. 2022;76:253\u201362. https:\/\/doi.org\/10.1007\/s12020-022-03025-8.","journal-title":"Endocrine"},{"key":"9893_CR19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n7","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hofmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n7.","journal-title":"BMJ"},{"key":"9893_CR20","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;28(l4898). https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"9893_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metaphor package. J Stat Soft. 2010;36:1\u201348. https:\/\/doi.org\/10.18637\/jss.v036.i03.","journal-title":"J Stat Soft"},{"issue":"3","key":"9893_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/MOL.0000000000000502","volume":"29","author":"B Ramms","year":"2018","unstructured":"Ramms B, Gordts PLSM. Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism. Curr Opi Lipidol. 2018;29(3):171\u20139. https:\/\/doi.org\/10.1097\/MOL.0000000000000502.","journal-title":"Curr Opi Lipidol"},{"issue":"5","key":"9893_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11883-021-00914-7","volume":"23","author":"I Akoumianakis","year":"2021","unstructured":"Akoumianakis I, Zvintzou E, Kypreos K, Filippatos TD. ANGPTL3 and apolipoprotein C-III as novel lipid-lowering targets. Curr Atheroscler Rep. 2021;23(5):20. https:\/\/doi.org\/10.1007\/s11883-021-00914-7.","journal-title":"Curr Atheroscler Rep"},{"issue":"6","key":"9893_CR24","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.2337\/diacare.27.6.1358","volume":"27","author":"GM Dallinga-Thie","year":"2004","unstructured":"Dallinga-Thie GM, Berk-Planken IIL, Bootsma AH, Jansen H. Atorvastatin decreases apolipoprotein C\u2013III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides. Diabetes Care. 2004;27(6):1358\u201364. https:\/\/doi.org\/10.2337\/diacare.27.6.1358.","journal-title":"Diabetes Care"},{"issue":"11","key":"9893_CR25","doi-asserted-by":"publisher","first-page":"e021508","DOI":"10.1136\/bmjopen-2018-021508","volume":"8","author":"A Sahebkar","year":"2019","unstructured":"Sahebkar A, Simental-Mend\u00eda LE, Katsiki N, Reiner \u017d, Banach M, Pirro M, et al. Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open. 2019;8(11):e021508. https:\/\/doi.org\/10.1136\/bmjopen-2018-021508.","journal-title":"BMJ Open"},{"issue":"1","key":"9893_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12944-017-0541-3","volume":"16","author":"J Oscarsson","year":"2017","unstructured":"Oscarsson J, Hurt-Camejo E. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Lipids Health Dis. 2017;16(1):149. https:\/\/doi.org\/10.1186\/s12944-017-0541-3.","journal-title":"Lipids Health Dis"},{"issue":"2","key":"9893_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/MED.0000000000000857","volume":"31","author":"J Chebli","year":"2024","unstructured":"Chebli J, Larouche M, Gaudet D. APOC3 siRNA and ASO therapy for dyslipidemia. Curr Opin Endocrinol Diabetes Obes. 2024;31(2):70\u20137. https:\/\/doi.org\/10.1097\/MED.0000000000000857.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"11","key":"9893_CR28","doi-asserted-by":"publisher","first-page":"e13841","DOI":"10.1111\/eci.13841","volume":"52","author":"I Calcaterra","year":"2022","unstructured":"Calcaterra I, Lupoli R, Di Minno A, Di Minno MND. Volanesorsen to treat severe hypertriglyceridaemia: a pooled analysis of randomized controlled trials. Eur J Clin Invest. 2022;52(11):e13841. https:\/\/doi.org\/10.1111\/eci.13841.","journal-title":"Eur J Clin Invest"},{"key":"9893_CR29","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jacl.2023.03.007","volume":"17","author":"JL Witztum","year":"2023","unstructured":"Witztum JL, Gaudet D, Arca M, Jones A, Soran H, Gouni-Berthold I, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: long-term efficacy and safety data from patients in an open-label extension trial. J Clin Lipidol. 2023;17:342\u201355. https:\/\/doi.org\/10.1016\/j.jacl.2023.03.007.","journal-title":"J Clin Lipidol"},{"issue":"10","key":"9893_CR30","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s11883-023-01140-z","volume":"25","author":"I Gouni-Berthold","year":"2023","unstructured":"Gouni-Berthold I, Schwarz J, Berthold HK. Updates in drug treatment of severe hypertriglyceridemia. Curr Atheroscler Rep. 2023;25(10):701\u20139. https:\/\/doi.org\/10.1007\/s11883-023-01140-z.","journal-title":"Curr Atheroscler Rep"},{"key":"9893_CR31","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S0140-6736(20)31310-6","volume":"396","author":"L Boxhoorn","year":"2020","unstructured":"Boxhoorn L, Voermans RP, Bouwense SA, Bruno MJ, Verdonk RC, Boermeester MA, et al. Acute pancreatitis. Lancet. 2020;396:726\u201334. https:\/\/doi.org\/10.1016\/S0140-6736(20)31310-6.","journal-title":"Lancet"},{"key":"9893_CR32","doi-asserted-by":"publisher","unstructured":"Carr RA, Rejowski BJ, Cote GA, Pitt HA, Zyromski NJ. Systematic review of hypertriglyceridemia-induced acute pancreatitis: A more virulent etiology? Pancreatology. 2016;16(4):469\u2013476. https:\/\/doi.org\/10.1016\/j.pan.2016.02.011.","DOI":"10.1016\/j.pan.2016.02.011."},{"issue":"5","key":"9893_CR33","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/MEG.0000000000002732","volume":"36","author":"Y Chen","year":"2024","unstructured":"Chen Y, Huang S, Luo B, Jiang J, Ren W, Zou K, et al. Prediction and evaluation of a nomogram model for recurrent acute pancreatitis. Eur J Gastroenterol Hepatol. 2024;36(5):554\u201362. https:\/\/doi.org\/10.1097\/MEG.0000000000002732.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"9893_CR34","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1177\/2050640618755002","volume":"6","author":"N de Pretis","year":"2018","unstructured":"de Pretis N, Amodio A, Frulloni L. Hypertriglyceridemic pancreatitis: Epidemiology, pathophysiology and clinical management. United Eur Gastroenterol J. 2018;6(5):649\u201355. https:\/\/doi.org\/10.1177\/2050640618755002.","journal-title":"United Eur Gastroenterol J"},{"issue":"6","key":"9893_CR35","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4103\/jfmpc.jfmpc_1426_21","volume":"11","author":"BGV Kumar","year":"2022","unstructured":"Kumar BGV, Prasad K, Singh D, Sethy PC. Hypertriglyceridemia induced acute pancreatitis: 4 years\u2019 experience from a tertiary care institute and quick literature review. J Family Med Prim Care. 2022;11(6):3360\u20137. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1426_21.","journal-title":"J Family Med Prim Care"},{"issue":"5","key":"9893_CR36","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1161\/CIRCULATIONAHA.105.591743","volume":"113","author":"A Kawakami","year":"2006","unstructured":"Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas FW, Sacks FM. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation. 2006;113(5):691\u2013700. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.591743.","journal-title":"Circulation"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-024-09893-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-024-09893-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-024-09893-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T19:04:05Z","timestamp":1728759845000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-024-09893-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,13]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["9893"],"URL":"https:\/\/doi.org\/10.1007\/s11154-024-09893-x","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,13]]},"assertion":[{"value":"3 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"WM, JPN and PC have served as a speaker from PTC therapeutics. The rest of the authors have no conflicts to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}